Wells Fargo & Company Biocept Inc Transaction History

Wells Fargo & Company

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.24 - $0.62 $0 - $1	2 Added 1.72%	118 $0
Q4 2022 Feb 13, 2023	BUY	$0.47 - $0.89 $1 - $3	4 Added 3.57%	116 $0
Q3 2022 Nov 14, 2022	SELL	$0.75 - $1.2 $0 - $1	-1 Reduced 0.88%	112 $0
Q2 2022 Aug 12, 2022	BUY	$0.88 - $2.27 $7 - $20	9 Added 8.65%	113 $0
Q1 2022 May 16, 2022	BUY	$1.83 - $3.97 $25 - $55	14 Added 15.56%	104 $0
Q4 2021 Feb 14, 2022	BUY	$3.43 - $4.22 $27 - $33	8 Added 9.76%	90 $0
Q3 2021 Nov 15, 2021	SELL	$3.39 - $4.34 $13 - $17	-4 Reduced 4.65%	82 $0
Q2 2021 Aug 16, 2021	SELL	$4.03 - $5.07 $4 - $5	-1 Reduced 1.15%	86 $0
Q4 2020 Feb 09, 2021	BUY	$4.31 - $6.16 $21 - $30	5 Added 6.1%	87 $0
Q3 2020 Nov 05, 2020	BUY	$3.61 - $11.4 $296 - $934	82 New	82 $0

Ticker BIOC
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 16,922,900
Market Cap $1.18M
Description
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.